Coretag Inc (COTI) Financier

Coretag, Inc. engages in the business of marketing and distribution of ladies’ fashion handbags. The company is headquartered in Liverpool, New York and currently employs 0 full-time employees. The company went IPO on 2015-11-17. The firm developed NTPT as a result of the discovery of a group of cyanine dyes which have selective targeting properties for intracellular proteins. These proteins become available for binding only when the cell membrane loses its integrity, which occurs once a cell has become necrotic. The firm has developed a portfolio of products that address high unmet needs in oncology. The firm develops targeted radiotherapy with 177Lu (lutetium) and 121Pb (lead) for the treatment of rapidly growing tumors and metastasis. The company also develops targeted diagnostics with 89Zr (zirconium) and 111In (indium) for detecting and quantifying necrotic tissue in the human body.